COVID-19 Research Companies Spur Interest in Biotech ETFs

COVID-19 Research Companies Spur Interest in Biotech ETFs

The coronavirus pandemic is having a profound impact on the healthcare sector in 2020, effects that ar

Israeli pain relief biotech PainReform files for a $25 million US IPO
Oncology biotech Revolution Medicines sets terms for $150 million IPO
Early stage biotech Passage Bio files for a $125 million IPO

The coronavirus pandemic is having a profound impact on the healthcare sector in 2020, effects that are clearly benefiting select biotechnology exchange traded funds.

Of course, structure matters, meaning that the biotechnology ETFs with the most impressive performances this year are the funds with most exposure to companies making progress on the coronavirus vaccine front. Fortunately for conservative investors, it’s not necessary to embrace the exotic in search of COVID-19 vaccine exposure.

The iShares Nasdaq Biotechnology ETF (IBB), the largest biotech ETF by assets, is about 12 percent year-to-date, proving that even broad-based, large-cap funds can be responsive to COVID-19 trends, assuming the fund is properly structured. 

“Pharmaceutical companies taking center stage in the COVID-19 fight have witnessed significant growth in their stock price in the first half of 2020,” notes AksjeBloggen. “According to data gathered by…

Click here for the full story.

COMMENTS

WORDPRESS: 0
DISQUS: